CAREDX INC. DL-,001 WKN: A118WG ISIN: US14167L1035 Kürzel: CDNA Forum: Aktien Thema: Hauptdiskussion

https://www.businesswire.com/news/home/20220602005408/en/CareDx-Leads-Transplant-Innovation-with-AiKidney-an-AI-Clinical-Decision-Support-Tool-for-Predicting-Allograft-Rejection-Risk

https://www.globenewswire.com/news-release/2022/05/24/2449070/31386/en/CareDx-Receives-CE-Mark-for-AlloSeq-HCT-for-Use-in-Hematopoietic-Cell-Transplantation.html

https://www.globenewswire.com/news-release/2022/05/17/2444754/31386/en/In-CareDx-Initiated-IP-Litigation-Against-Natera-Natera-Now-Drops-1-of-2-Patents-Originally-Asserted-Against-CareDx.html

CareDx Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/05/2437284/31386/en/CareDx-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/05/2436571/31386/en/CareDx-Validates-Clinical-Performance-of-AlloMap-Kidney-to-Comprehensively-Assess-Transplant-Rejection.html

https://www.globenewswire.com/news-release/2022/04/14/2422640/31386/en/CareDx-Reports-Over-200-000-Heart-Transplant-Patient-Results-Served.html CareDx Reports Over 200,000 Heart Transplant Patient Results Served CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States

https://www.globenewswire.com/news-release/2022/04/11/2419896/31386/en/CareDx-the-Leading-Sponsor-of-UNOS-Transplant-Management-Forum-Demonstrates-the-Value-of-Digital-Solutions-to-Improve-Pre-Transplant-Patient-Referral-and-Waitlisting-Workflow.html

https://www.globenewswire.com/news-release/2022/03/30/2412689/31386/en/CareDx-Partners-with-the-European-Society-for-Organ-Transplantation-to-Provide-Clinical-Evidence-Supporting-the-Use-of-AlloSeq-cfDNA-with-European-Transplant-Healthcare-Professiona.html

https://www.globenewswire.com/news-release/2022/03/24/2409242/0/en/CareDx-s-AlloCare-App-Now-Integrated-with-TxAccess-to-Help-Pre-Transplant-Patients-Navigate-the-Waitlist-Process.html

CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; ... https://www.bakersfield.com/ap/news/caredx-wins-44-9m-in-damages-in-false-advertising-trial-against-natera-natera-intentionally/article_8849930e-0d01-591f-b643-3ba8c4035548.html

CareDx Announces Cibiltech Initiates CIBIL Study Using iBox Artificial Intelligence to Monitor Kidney Transplant Patients https://www.globenewswire.com/news-release/2022/03/03/2396118/31386/en/CareDx-Announces-Cibiltech-Initiates-CIBIL-Study-Using-iBox-Artificial-Intelligence-to-Monitor-Kidney-Transplant-Patients.html Results from CareDx’s OKRA Study and Cibiltech’s CIBIL Study will Demonstrate Clinical Utility of iBox for Transplant Patient Management

https://www.globenewswire.com/news-release/2022/03/02/2395224/31386/en/CareDx-Partners-with-the-National-Kidney-Foundation-to-Advocate-for-Kidney-Transplant-Patients.html

CareDx Reports Fourth Quarter and Full Year 2021 Results https://www.streetinsider.com/dr/news.php?id=19673878&gfv=1

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation https://www.globenewswire.com/news-release/2022/02/22/2389123/31386/en/CareDx-Leads-the-Way-in-Xenotransplant-Organ-Surveillance-in-Monitoring-World-s-First-Successful-Living-Xenotransplantation.html CareDx’s Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health

CareDx Joins Forces with MOTTEP, The National Minority Organ Tissue Transplant Education ... https://www.bakersfield.com/ap/news/caredx-joins-forces-with-mottep-the-national-minority-organ-tissue-transplant-education/article_155404b3-04ad-5e7e-9d14-9e05ff4e7371.html

CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes https://www.globenewswire.com/news-release/2021/12/16/2353476/31386/en/CareDx-Enrolls-First-Patient-in-LungCare-Registry-Study-to-Measure-Impact-of-Multimodality-Assessment-on-Lung-Transplant-Patient-Outcomes.html 1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection